Safety and Response after Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE for Neuroendocrine Tumors in Phase 1/2 Prospective Japanese Trial.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepato-biliary-pancreatic sciences"
DOI: 10.1002/jhbp.1101
Abstract: BACKGROUND The present prospective phase 1/2 study aimed to elucidate the efficacy and safety of 177 Lu-DOTATATE (four cycles of 7.4 GBq) in Japanese patients with unresectable, progressive neuroendocrine tumors (NETs). METHODS From April 2018… read more here.
Keywords: dotatate; safety; response; neuroendocrine tumors ... See more keywords
Comparison of Voxel S-Value Methods for Personalized Voxel-based Dosimetry of 177 Lu-DOTATATE.
Sign Up to like & getrecommendations! Published in 2022 at "Medical physics"
DOI: 10.1002/mp.15444
Abstract: PURPOSE Voxel-based dosimetry is potentially accurate than organ-based dosimetry because it considers the anatomical variations in each individual and the heterogeneous radioactivity distribution in each organ. Here, voxel-based dosimetry for 177 Lu-DOTATATE therapy was performed… read more here.
Keywords: vsv; based dosimetry; 177 dotatate; dosimetry ... See more keywords
Abstract CT194: ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct194
Abstract: Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitization. ETCTN… read more here.
Keywords: lutetium 177; dotatate; 177 dotatate; triapine ... See more keywords
Lutetium Lu 177 Dotatate Approved by FDA.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-021
Abstract: The FDA recently approved the radiopharmaceutical lutetium Lu 177 dotatate to treat patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The approval was based on results of the phase III NETTER-1 trial. read more here.
Keywords: approved fda; 177 dotatate; dotatate approved; lutetium 177 ... See more keywords
Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma/paraganglioma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps4159
Abstract: TPS4159 Background: Pheochromocytoma/paraganglioma (PHEO/PGL) is a rare malignancy that arises from chromaffin cells of typically the adrenal medulla but can also be of extra-adrenal origin. These tumors produce excessive catecholamines such as epinephrine and norepinephrine… read more here.
Keywords: dotatate; pheo pgl; pheochromocytoma paraganglioma; 177 dotatate ... See more keywords
Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14102513
Abstract: Simple Summary Neuroendocrine tumors (NETs) expressing the somatostatin receptor subtype 2 (SSTR2) are promising targets for peptide receptor radionuclide therapy (PRRT) using the somatostatin analogue Lu-177-DOTATATE. Patients expressing low levels of SSTR2 do not benefit… read more here.
Keywords: cell; expression; 177 dotatate; heksst2 cells ... See more keywords